Abstract
Objective
To assess the efficacy and safety of intravitreal aflibercept injection in the treatment
of CNV secondary to presumed ocular histoplasmosis syndrome (POHS).
Purpose
To assess safety of intravitreal aflibercept for the treatment of CNV secondary to
presumed ocular histoplasmosis syndrome.
Methods
Masked, open-label, prospective study. Five subjects will receive 2.0 mg aflibercept
injection every 8 weeks with 3 initial monthly doses over a 12 month period.
Results
No adverse systemic or ocular were reported. At month six, the mean visual acuity
improved by 7.8 ETDRS letters, mean central subfoveal thickness decreased by 38.8
microns and mean OCT volume decreased by 0.076 mm3 . At month twelve, the mean visual
acuity improved by12.4 ETDRS letters, mean central subfoveal thickness decreased by
34.6 microns and mean OCT volume decreased by 0.576 mm3.
Conclusion
The use of intravitreal 2.0 mg aflibercept injection for the treatment of CNV secondary
to presumed ocular histoplasmosis syndrome yielded no systemic or ocular adverse events
and produced improvement in visual acuity and reduction of OCT thickness and volume.
Résumé
Objectif
Évaluer l’efficacité et l’innocuité de l’aflibercept intravitréen pour le traitement
de la néovascularisation choroïdienne (NVC) secondaire au syndrome d’histoplasmose
oculaire.
Nature
Étude prospective ouverte à l’insu.
Méthodes
Cinq sujets ont reçu 2,0 mg d’aflibercept intravitréen aux 8 semaines, avec 3 doses
mensuelles initiales, sur une période de 12 mois.
Résultats
Aucun événement indésirable, d’ordre systémique ou oculaire, n’a été noté. Au sixième
mois, l’acuité visuelle moyenne s’était améliorée de 7,8 lettres ETDRS, l’épaisseur
sous-fovéale centrale moyenne avait diminué de 38,8 microns et le volume TCO moyen
avait diminué de 0,076 mm3. Au douzième mois, l’acuité visuelle moyenne s’était améliorée
de 12,4 lettres ETDRS, l’épaisseur sous-fovéale centrale moyenne avait diminué de
34,6 microns et le volume TCO moyen avait diminué de 0,576 mm3.
Conclusion
L’administration de doses de 2,0 mg d’aflibercept intravitréen pour le traitement
de la NVC secondaire au syndrome d’histoplasmose oculaire n’a donné lieu à aucun événement
indésirable, d’ordre systémique ou oculaire, et a produit une amélioration de l’acuité
visuelle et une réduction de l’épaisseur et du volume mesurés par TCO.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of OphthalmologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Subfoveal and juxtafoveal subretinal neovascularization in the presumed ocular histoplasmosis syndrome.Ophthalmology. 1984; 91: 1592
- Subfoveal neovascularization in the ocular histoplasmosis syndrome: a natural history study.Retina. 1988; 8: 225
- Ocular Histoplasmosis Study. Argon laser photocoagulation for ocular histoplasmosis: results of a randomized clinical trial. Arch Ophthalmol. 1983;101:1347–57.
- Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis: results of a randomized clinical trial. Arch Ophthalmol. 1987;105:1499–1507.
- Surgical removal vs observation for idiopathic or ocular histoplasmosis syndrome-associated subfoveal choroidal neovascularization: Vision Preference Value Scale findings from the randomized SST Group H Trial: SST Report No.17.Arch Ophthalmol. 2008; 126: 1626-1632
- Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I. Ophthalmic findings from a randomized clinical trial: Submacular Surgery Trials (SST) Group H Trial: SST Report No. 9.Arch Ophthalmol. 2004; 122: 1597-1611
- Submacular surgery for subfoveal choroidal neovascular membranes in patients with presumed ocular histoplasmosis.Arch Ophthalmol. 1997; 115: 991-996
- Visual results after surgical removal of subfoveal choroidal neovascular membranes.Ophthalmology. 1994; 101: 1384-1396
- Surgical removal of subfoveal choroidal neovascularization in presumed ocular histoplasmosis: stability of early visual results.Ophthalmology. 1997; 104: 22-26
- Photodynamic therapy for juxtafoveal chorodial neovascularization due to ocular histoplasmosis syndrome.Retina. 2005; 25: 26-32
- Ocular photodynamic therapy with verteporfin for choroidal neovascularization secondary to ocular histoplasmosis syndrome.Retina. 2003; 23: 299-306
- Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis.Am J Ophthalmol. 2008; 145: 875-878
- Ranibizumab versus photodynamic therapy for presumed ocular histoplasmosis.Ophthalmic Surg Lasers Imaging Retina. 2013; 44: 17-21
- Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome.Am J Ophthalmol. 2003; 136: 739-741
- Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization.J Ocul Pharmacol Ther. 1999; 15: 425-428
- Photodynamic therapy of subfoveal and juxtafoveal choroidal neovascularization in ocular histoplasmosis syndrome: a retrospective case series.Retina. 2004; 24: 863-870
- Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to ocular histoplasmosis syndrome.Retina. 2012; 32: 468-472
- Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular hisotplasmosis syndrome.Retina. 2009; 29: 1418-1423
- Analysis of outcomes for intravitreal bevacizumab in the treatment of chorodial neovascularization secondary to ocular histoplasmosis.Ophthalmology. 2012; 119: 327-332
Article info
Publication history
Accepted:
November 22,
2015
Received:
October 3,
2015
Identification
Copyright
© 2016 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.
